Methylglyoxal Evaluation in Humans (NCT05350553) | Clinical Trial Compass
CompletedNot Applicable
Methylglyoxal Evaluation in Humans
United States39 participantsStarted 2022-05-02
Plain-language summary
The investigators will test the hypothesis that patients with low back pain associated with lumbar disc aberrancy will have elevated MGO-protein levels circulating in the blood that are comparable to patients with painful diabetic neuropathy.
Who can participate
Age range45 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Informed consent provided by the subject
* Able to read/speak English
* TYPE 2 DIABETES
* All healthy inclusion criteria AND
* Blood glucose levels \> 126 mg/dl
* Diagnosed with neuropathy or experience painful numbness or tingling in their hands or feet
* LOW BACK PAIN
* All healthy inclusion criteria AND
* Chronic (persistent pain lasting longer than 3 months) low back pain as a direct result of non-operative lumbar disc aberrancy (disc herniation, protrusion, or extrusion)
* Aberrancy occurring within 12 months of pre-screening
Exclusion Criteria:
* Prisoner
* Current clinically significant cardiac or neurological disease
* Diagnosis of IBS, osteoarthritis, fibromyalgia, complex regional pain syndrome (CRPS), postherpetic neuralgia
* Lumbar surgery due to disc aberrancy
* Therapeutic spinal injections within the last 3 months (steroid, ablations, etc.)
* Chronic use of steroids or non
* steroidal anti-inflammatory drugs (NSAIDS) within 3 months of pre-screen
* Past or present use of spinal cord stimulators